Safety and efficacy of mogamulizumab in patients with adult T-cell leukemia–lymphoma in Japan: interim results of postmarketing all-case surveillance

[1]  J. Kato,et al.  Late onset toxic epidermal necrolysis induced by mogamulizumab, an anti‐CC chemokine receptor 4 antibody for the treatment of adult T‐cell leukaemia/lymphoma , 2017, Hematological oncology.

[2]  M. Seto,et al.  Cutaneous Adverse Reaction to Mogamulizumab May Indicate Favourable Prognosis in Adult T-cell Leukaemia-lymphoma. , 2016, Acta dermato-venereologica.

[3]  A. Utsunomiya,et al.  Pretransplantation Anti-CCR4 Antibody Mogamulizumab Against Adult T-Cell Leukemia/Lymphoma Is Associated With Significantly Increased Risks of Severe and Corticosteroid-Refractory Graft-Versus-Host Disease, Nonrelapse Mortality, and Overall Mortality. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  K. Akashi,et al.  Mogamulizumab Treatment Prior to Allogeneic Hematopoietic Stem Cell Transplantation Induces Severe Acute Graft-versus-Host Disease. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  S. Fuji,et al.  Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality , 2016, Bone Marrow Transplantation.

[6]  S. Yamasaki,et al.  Administration of an anti-CC chemokine receptor 4 monoclonal antibody, mogamulizumab, before allogeneic bone marrow transplantation for adult T-cell leukemia/lymphoma , 2016, Bone Marrow Transplantation.

[7]  M. Taniwaki,et al.  Toxic epidermal necrolysis in adult T cell leukemia/lymphoma treated with mogamulizumab , 2016, Annals of Hematology.

[8]  Kenji Matsumoto,et al.  Cytomegalovirus Pneumonia after Anti-CC-chemokine Receptor 4 Monoclonal Antibody (Mogamulizumab) Therapy in an Angioimmunoblastic T-cell Lymphoma Patient. , 2016, Internal medicine.

[9]  K. Karube,et al.  Recurrence of Psoriasis Vulgaris Accompanied by Treatment with C-C Chemokine Receptor Type 4 (CCR4) Antibody (Mogamulizumab) Therapies in a Patient with Adult T cell Leukemia/ Lymphoma: Insight into Autoinflammatory Diseases. , 2016, Internal medicine.

[10]  S. Hanada,et al.  Treatment and survival among 1594 patients with ATL. , 2015, Blood.

[11]  S. Iida,et al.  Fatal reactivation of hepatitis B virus infection in a patient with adult T‐cell leukemia–lymphoma receiving the anti‐CC chemokine receptor 4 antibody mogamulizumab , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[12]  G. Gibney,et al.  Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes , 2015, Clinical Cancer Research.

[13]  H. Masuzaki,et al.  Fatal pneumonia and viremia due to human parainfluenza virus type 1 in a patient with adult T-cell leukemia–lymphoma treated with mogamulizumab , 2015, Journal of Infection and Chemotherapy.

[14]  T. Honda,et al.  Stevens-Johnson Syndrome Associated with Mogamulizumab-induced Deficiency of Regulatory T cells in an Adult T-cell Leukaemia Patient. , 2015, Acta dermato-venereologica.

[15]  R. Ueda,et al.  Dose‐intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T‐cell leukaemia‐lymphoma: a randomized phase II study , 2015, British journal of haematology.

[16]  S. Iida,et al.  Reactivation of hepatitis B virus (HBV) infection in adult T-cell leukemia–lymphoma patients with resolved HBV infection following systemic chemotherapy , 2015, International Journal of Hematology.

[17]  K. Tobinai,et al.  Human T-cell Lymphotropic Virus Type I–Associated Adult T-cell Leukemia–Lymphoma: New Directions in Clinical Research , 2014, Clinical Cancer Research.

[18]  K. Ishitsuka,et al.  Human T-cell leukaemia virus type I and adult T-cell leukaemia-lymphoma. , 2014, The Lancet. Oncology.

[19]  M. Taniwaki,et al.  Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Y. Takatsuka,et al.  Effect of anti‐CCR4 monoclonal antibody (mogamulizumab) on adult T‐cell leukemia–lymphoma: Cutaneous adverse reactions may predict the prognosis , 2014, The Journal of dermatology.

[21]  Takahiro Kumode,et al.  Induction of molecular remission by using anti-CC-chemokine receptor 4 (anti-CCR4) antibodies for adult T-cell leukemia: a risk of opportunistic infection after treatment with anti-CCR4 antibodies , 2014, Retrovirology.

[22]  S. Lim,et al.  Cytomegalovirus infection and end-organ disease in Asian patients with lymphoma receiving chemotherapy , 2014, Leukemia & lymphoma.

[23]  K. Akashi,et al.  Successful treatment with anti-CC chemokine receptor 4 MoAb of relapsed adult T-cell leukemia/lymphoma after umbilical cord blood transplantation , 2013, Bone Marrow Transplantation.

[24]  紀夫 林,et al.  B型肝炎治療ガイドライン（第1.1版） , 2013 .

[25]  S. Iida,et al.  Stevens–Johnson Syndrome associated with mogamulizumab treatment of adult T‐cell leukemia / lymphoma , 2013, Cancer science.

[26]  R. Ueda,et al.  Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: a multicenter phase II study. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  K. Ohshima,et al.  Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  T. Shiohara,et al.  Defective Regulatory T Cells In Patients with Severe Drug Eruptions: Timing of the Dysfunction Is Associated with the Pathological Phenotype and Outcome1 , 2009, The Journal of Immunology.

[29]  K. Yamaguchi,et al.  Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma: a proposal from an international consensus meeting. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Sano,et al.  Prevention of toxic epidermal necrolysis by regulatory T cells , 2005, European journal of immunology.

[31]  S. Iida,et al.  Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  K. Tobinai.  CHEMOTHERAPY OF ATL , 2003 .

[33]  K. Matsushima,et al.  Frequent expression of CCR4 in adult T-cell leukemia and human T-cell leukemia virus type 1-transformed T cells. , 2002, Blood.

[34]  M. Shimoyama,et al.  Diagnostic criteria and classification of clinical subtypes of adult T‐cell leukaemia‐lymphoma , 1991, British journal of haematology.

[35]  J. Yodoi,et al.  Adult T-cell leukemia: clinical and hematologic features of 16 cases. , 1977, Blood.